

**FOR IMMEDIATE RELEASE**

## **Sun Pharma reports Q4 & full year results for FY26**

*Q4 Sales at Rs. 145,598 million up 13.6% YoY  
Q4 Net profit was Rs. 27,140 million, up 26.2% YoY*

Mumbai, May 22, 2026: Sun Pharmaceutical Industries Limited (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715) reported financials for the fourth quarter ending March 31<sup>st</sup>, 2026.

### **Highlights of Q4FY26 consolidated financials\***

- Sales at Rs. 145,598 million, a growth of 13.6%
- Global Innovative Medicines\*\* sales at US\$ 354 million.
- Global Innovative Medicines sales up 20.1%, accounting for 22.2% of sales.
- EBITDA was Rs. 39,542 million, up 6.4%. EBITDA margin was 27.1%.
- Net profit was Rs. 27,140 million, up 26.2%
- R&D investment was Rs. 9,757 million at 6.7% of sales

### **Highlights of FY26 consolidated financials\***

- Sales at Rs. 582,201 million, a growth of 11.9%
- Global Innovative Medicines\*\* sales at US\$ 1,420 million
- Global Innovative Medicines sales up 16.4%, accounting for 20.7% of sales, both Ex-milestone.
- EBITDA was Rs. 177,314 million, up 16.1%. EBITDA margin was 30.3%.
- Net profit was Rs. 114,794 million, up 5.0%
- R&D investment was Rs. 35,540 million at 6.1% of sales

*\*Growth measured vs same period last financial year/ \*\* “Specialty” business renamed as “Innovative Medicines”*

These results were taken on record by the Board of Directors at a meeting held today. The Board has proposed a final dividend of Rs. 5.00 per share for the year FY26. This is in addition to the interim dividend of Rs. 11.00 per share paid in FY26, taking the total dividend for FY26 to Rs. 16.00 per share, same as FY25.

Kirti Ganorkar, Managing Director of the Company, said, “Our full-year performance reflects several significant achievements. Sun’s 0.3 percentage point gain in the India market is our highest gain since the Ranbaxy acquisition. Our U.S. Innovative Medicines business has surpassed USD 1 billion in revenues, while Ex-US Innovative Medicines continues to demonstrate strong growth momentum. The recently announced Organon acquisition is expected to further accelerate Sun’s transformation into a leading global pharmaceutical company.”

### **India Formulations**

Formulation sales in India were Rs. 48,359 million, registering a growth of 14.8%. India Formulation sales accounted for 33.2% of total consolidated sales. For the full year FY26, sales were Rs. 192,904 million, growing 14%.

Sun Pharma continues to be India’s No. 1 Pharma Company. Sun’s market share increased from 8.1% to 8.4%, as per the Pharmarack MAT Mar-2026 report. As per SMSRC (Nov-Feb 2026) report, Sun Pharma enjoys No.1 ranking by prescriptions in 11 different doctor categories. The company launched 11 new products during the quarter and 37 products in the full year.



## **US Formulations**

Formulation sales in the US were US\$ 459 million, lower by 1.1%. Innovative Medicines continued to grow offsetting the decline in generics business. US sales accounted for approximately 28.8% of total consolidated sales. For the full year FY26, sales were US\$ 1,904 million.

## **Emerging Markets (EM) Formulations**

Emerging Markets formulations sales were US\$ 306 million, up by 17.4% and accounted for 19.2% of total consolidated sales. For the full year FY26, sales were US\$ 1,265 million, growing 13.6%.

## **Rest of World (ROW) Formulations**

Formulation sales in Rest of World markets were US\$ 220 million, up by 10% and accounted for 13.8% of total consolidated sales. For the full year FY26, sales were US\$ 969 million, up 14.4%.

## **Innovative Medicines**

Global Innovative Medicines sales were US\$ 354 million for Q4FY26, up 20.1% and accounted for 22.2% of sales. For the full year FY26, sales were US\$ 1,420 million, up 16.8%.

## **Active Pharmaceutical Ingredients (API)**

Our API portfolio supports our formulation business and API customers across geographies. External sales of API were Rs. 6,739 million, up 26.4%. For the full year FY26, API sales were Rs. 21,853 million, up 2.6%.

## **R&D Update**

Sun Pharma's R&D efforts span across both innovative and generic businesses and the company continues to invest in building the pipeline for various markets. Sun's innovative R&D pipeline includes five novel entities in clinical stage. Sun has a comprehensive product offering in the US market consisting of approved ANDAs for 552 products while filings for 122 ANDAs await US FDA approval, including 28 tentative approvals. During the quarter, 7 ANDAs were filed, and approval received for 2 ANDAs.

Sun's portfolio includes 57 approved NDAs while 13 NDAs await US FDA approval.

## Innovative Medicines Pipeline

Candidate	Indication	Current phase	Next milestone
Ilumya	psoriatic arthritis	Supplement filed with US FDA	PDUFA Date: Oct-26
Fibromun	soft tissue sarcoma	Phase 2 completed	Start of Phase 3
	glioblastoma	Phase 2	Regulatory filing
GL0034	type 2 diabetes	Phase 2	Topline data during 2HCY27
Nidlegly™ (EU, ANZ rights with Sun)	locally advanced melanoma	Phase 3 completed	Filing with EMA
	locally advanced BCC	Phase 2	Regulatory filing
	locally advanced cSCC	Phase 2	Regulatory filing
<b>Candidate for partnering</b>			
MM-II	pain in osteoarthritis	Phase 2 completed	To enter partnership for commercialization

## Sales and R&D snapshot

(₹ in mn)

Particulars	Quarter ended			Year ended	
	31.03.2026	31.12.2025	31.03.2025	31.03.2026	31.03.2025
India Formulations	48,358.9	49,985.8	42,129.6	192,903.6	169,230.0
US Formulations	41,997.1	42,505.1	40,204.1	168,242.2	162,402.8
EM Formulations	27,970.5	29,996.0	22,561.2	111,864.8	94,159.8
ROW Formulations	20,139.7	26,393.5	17,339.7	85,684.0	71,626.0
<b>Total Formulations</b>	<b>138,466.2</b>	<b>148,880.4</b>	<b>122,234.6</b>	<b>558,694.6</b>	<b>497,418.6</b>
API	6,738.6	5,411.6	5,330.3	21,852.6	21,292.2
Others	392.7	398.7	590.9	1,653.9	1,701.7
<b>Total Sales</b>	<b>145,597.5</b>	<b>154,690.7</b>	<b>128,155.8</b>	<b>582,201.1</b>	<b>520,412.5</b>
<b>Total R&amp;D Expenditure</b>	<b>9,757.3</b>	<b>8,927.7</b>	<b>8,165.5</b>	<b>35,540.1</b>	<b>32,484.4</b>
Capital	257.0	208.6	261.5	799.1	942.5
Revenue	9,500.3	8,719.1	7,904.0	34,741.0	31,541.9
Exchange Rates: US\$ 1 = ₹	91.49	89.11	86.62		

Sun Pharmaceutical Industries Limited  
SUN HOUSE, Plot No. 201 B/1,  
Western Express Highway, Goregaon (E),  
Mumbai 400063, India  
Tel.: (91-22) 4324 4324 Fax.: (91-22) 4324 4343  
Website: [www.sunpharma.com](http://www.sunpharma.com)  
Email: [secretarial@sunpharma.com](mailto:secretarial@sunpharma.com)  
CIN: L24230GJ1993PLC019050



### **Earnings Call** (06.30 pm IST, May 22, 2026)

The Company will host earnings call at 06.30 pm IST on May 22, 2026, where senior management will discuss the Company's performance and answer questions from participants. This call will be accessible through an audio dial-in and a webcast.

*Audio conference* Participants can dial-in on the numbers below  
Universal number: +91 22 6629 0049  
+91 22 7194 5729

*Pre-registration details* Click here [DiamondPassRegistration](#)

*Webcast* More details will be provided through our website, [www.sunpharma.com](http://www.sunpharma.com)

To participate in the audio call, please dial the numbers provided above five to ten minutes ahead of the scheduled start time. The operator will provide instructions on asking questions before the call. The transcript of the event will be available at [www.sunpharma.com](http://www.sunpharma.com). The playback will be available for a few days.

### **Disclaimer**

Statements in this "Document" describing the Company's objectives, projections, estimates, expectations, plans or predictions or industry conditions or events may be "forward looking statements" within the meaning of applicable securities laws and regulations. Actual results, performance or achievements could differ materially from those expressed or implied. The Company undertakes no obligation to update or revise forward looking statements to reflect developments or circumstances that arise or to reflect the occurrence of unanticipated developments/circumstances after the date hereof.

### **About Sun Pharmaceutical Industries Limited (CIN - L24230GJ1993PLC019050)**

Sun Pharma is the world's leading specialty generics company with a presence in Innovative Medicines, Generics and Consumer Healthcare products. It is the largest pharmaceutical company in India and is a leading generic company in the US as well as Global Emerging Markets. Sun's high growth Innovative Medicines portfolio spans innovative products in dermatology, ophthalmology, and onco-dermatology and accounts for about 22% of company sales. The company's vertically integrated operations deliver high-quality medicines, trusted by physicians and consumers in over 100 countries. Its manufacturing facilities are spread across five continents. Sun Pharma is proud of its multi-cultural workforce drawn from over 50 nations. For further information, please visit [www.sunpharma.com](http://www.sunpharma.com) and follow us on LinkedIn & X (Formerly Twitter).

### **Contacts**

#### **Investors**

Dr. Abhishek Sharma  
Tel +91 22 4324 4324, Xtn 2929  
Tel Direct +91 22 4324 2929  
Mobile +91 98196 86016  
E mail [abhi.sharma@sunpharma.com](mailto:abhi.sharma@sunpharma.com)

#### **Media**

Gaurav Chugh  
Tel +91 22 4324 4324, Xtn 5373  
Tel Direct +91 22 4324 5373  
Mobile +91 98104 71414  
E mail [gaurav.chugh@sunpharma.com](mailto:gaurav.chugh@sunpharma.com)